285 related articles for article (PubMed ID: 20733093)
1. Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels.
Kappers MH; van Esch JH; Sluiter W; Sleijfer S; Danser AH; van den Meiracker AH
Hypertension; 2010 Oct; 56(4):675-81. PubMed ID: 20733093
[TBL] [Abstract][Full Text] [Related]
2. Receptor tyrosine kinase inhibition, hypertension, and proteinuria: is endothelin the smoking gun?
Dhaun N; Webb DJ
Hypertension; 2010 Oct; 56(4):575-7. PubMed ID: 20733091
[No Abstract] [Full Text] [Related]
3. The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system.
Kappers MH; Smedts FM; Horn T; van Esch JH; Sleijfer S; Leijten F; Wesseling S; Strevens H; Jan Danser AH; van den Meiracker AH
Hypertension; 2011 Aug; 58(2):295-302. PubMed ID: 21670421
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib malate for the treatment of metastatic renal cell carcinoma and gastrointestinal stromal tumors.
Adams VR; Leggas M
Clin Ther; 2007 Jul; 29(7):1338-53. PubMed ID: 17825686
[TBL] [Abstract][Full Text] [Related]
5. Sunitinib, a receptor tyrosine kinase inhibitor, increases blood pressure in rats without associated changes in cardiac structure and function.
Blasi E; Heyen J; Patyna S; Hemkens M; Ramirez D; John-Baptiste A; Steidl-Nichols J; McHarg A
Cardiovasc Ther; 2012 Oct; 30(5):287-94. PubMed ID: 21884012
[TBL] [Abstract][Full Text] [Related]
6. Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress.
Kappers MH; de Beer VJ; Zhou Z; Danser AH; Sleijfer S; Duncker DJ; van den Meiracker AH; Merkus D
Hypertension; 2012 Jan; 59(1):151-7. PubMed ID: 22124432
[TBL] [Abstract][Full Text] [Related]
7. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.
Kappers MH; van Esch JH; Smedts FM; de Krijger RR; Eechoute K; Mathijssen RH; Sleijfer S; Leijten F; Danser AH; van den Meiracker AH; Visser TJ
J Clin Endocrinol Metab; 2011 Oct; 96(10):3087-94. PubMed ID: 21816788
[TBL] [Abstract][Full Text] [Related]
8. Greater Sensitivity of Blood Pressure Than Renal Toxicity to Tyrosine Kinase Receptor Inhibition With Sunitinib.
Lankhorst S; Baelde HJ; Kappers MH; Smedts FM; Hansen A; Clahsen-van Groningen MC; Sleijfer S; Mathijssen RH; Danser AH; van den Meiracker AH
Hypertension; 2015 Sep; 66(3):543-9. PubMed ID: 26195484
[TBL] [Abstract][Full Text] [Related]
9. Impaired coronary flow reserve in metastatic cancer patients treated with sunitinib.
Sen F; Yildiz I; Basaran M; Ekenel M; Oz F; Kilic L; Toz B; Gurdal A; Camlica H; Bavbek S; Oflaz H
J BUON; 2013; 18(3):775-81. PubMed ID: 24065498
[TBL] [Abstract][Full Text] [Related]
10. Impaired endothelium-dependent vasodilation does not initiate the development of sunitinib-associated hypertension.
Thijs AM; van Herpen CM; Verweij V; Pertijs J; van den Broek PH; van der Graaf WT; Rongen GA
J Hypertens; 2015 Oct; 33(10):2075-82. PubMed ID: 26203967
[TBL] [Abstract][Full Text] [Related]
11. Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study.
Lankhorst S; Kappers MH; van Esch JH; Smedts FM; Sleijfer S; Mathijssen RH; Baelde HJ; Danser AH; van den Meiracker AH
Hypertension; 2014 Dec; 64(6):1282-9. PubMed ID: 25185126
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib: from rational design to clinical efficacy.
Chow LQ; Eckhardt SG
J Clin Oncol; 2007 Mar; 25(7):884-96. PubMed ID: 17327610
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
14. Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension.
Eechoute K; van der Veldt AA; Oosting S; Kappers MH; Wessels JA; Gelderblom H; Guchelaar HJ; Reyners AK; van Herpen CM; Haanen JB; Mathijssen RH; Boven E
Clin Pharmacol Ther; 2012 Oct; 92(4):503-10. PubMed ID: 22948895
[TBL] [Abstract][Full Text] [Related]
15. Effect of high salt diet on blood pressure and renal damage during vascular endothelial growth factor inhibition with sunitinib.
Lankhorst S; Baelde HJ; Clahsen-van Groningen MC; Smedts FM; Danser AH; van den Meiracker AH
Nephrol Dial Transplant; 2016 Jun; 31(6):914-21. PubMed ID: 26681729
[TBL] [Abstract][Full Text] [Related]
16. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib.
Chu TF; Rupnick MA; Kerkela R; Dallabrida SM; Zurakowski D; Nguyen L; Woulfe K; Pravda E; Cassiola F; Desai J; George S; Morgan JA; Harris DM; Ismail NS; Chen JH; Schoen FJ; Van den Abbeele AD; Demetri GD; Force T; Chen MH
Lancet; 2007 Dec; 370(9604):2011-9. PubMed ID: 18083403
[TBL] [Abstract][Full Text] [Related]
17. Rho kinase inhibition mitigates sunitinib-induced rise in arterial pressure and renal vascular resistance but not increased renal sodium reabsorption.
Grisk O; Koenen A; Meissner T; Donner A; Braun D; Steinbach A; Glöckl G; Zimmermann U; Evert K; Evert M; Katsari E; Löhn M; Plettenburg O; Rettig R
J Hypertens; 2014 Nov; 32(11):2199-210; discussion 2110. PubMed ID: 25275248
[TBL] [Abstract][Full Text] [Related]
18. Home blood-pressure monitoring in patients receiving sunitinib.
Azizi M; Chedid A; Oudard S
N Engl J Med; 2008 Jan; 358(1):95-7. PubMed ID: 18172185
[No Abstract] [Full Text] [Related]
19. Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma.
Rock EP; Goodman V; Jiang JX; Mahjoob K; Verbois SL; Morse D; Dagher R; Justice R; Pazdur R
Oncologist; 2007 Jan; 12(1):107-13. PubMed ID: 17227905
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib-induced hyperammonemic encephalopathy in gastrointestinal stromal tumors.
Lee NR; Yhim HY; Yim CY; Kwak JY; Song EK
Ann Pharmacother; 2011 Oct; 45(10):e56. PubMed ID: 21954449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
